Should I buy or sell Inventiva stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares. View IVA analyst ratings or view top-rated stocks .

What is Inventiva's stock price target for 2024?

7 brokers have issued 1-year price targets for Inventiva's stock. Their IVA share price targets range from $11.00 to $35.00. On average, they expect the company's stock price to reach $16.40 in the next year. This suggests a possible upside of 267.7% from the stock's current price. View analysts price targets for IVA or view top-rated stocks among Wall Street analysts .

How have IVA shares performed in 2023?

Inventiva's stock was trading at $4.46 at the start of the year. Since then, IVA stock has increased by 0.0% and is now trading at $4.46. View the best growth stocks for 2023 here .

When did Inventiva IPO?

(IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Who are Inventiva's major shareholders?

Inventiva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.05%).

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Inventiva Stock Price, News & Analysis (NASDAQ:IVA)

$4.46

+0.14 (+3.24%)

(As of 12/4/2023 ET)

Compare

Today's Range: $4.33
▼
$4.49
50-Day Range: $3.62
▼
$4.46
52-Week Range: $2.22
▼
$6.82

Volume: 9,066 shs
Average Volume: 51,238 shs
Market Capitalization: $230.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.40

Inventiva MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 267.7% Upside
$16.40 Price Target
Short Interest: Healthy
0.17% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.21) to ($2.07) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

365th out of 952 stocks

Pharmaceutical Preparations Industry

162nd out of 434 stocks

3.5

Analyst's Opinion

Consensus Rating
Inventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.40, Inventiva has a forecasted upside of 267.7% from its current price of $4.46.
Amount of Analyst Coverage
Inventiva has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.17% of the outstanding shares of Inventiva have been sold short.
Short Interest Ratio / Days to Cover
Inventiva has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Inventiva has recently decreased by 1.21%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Inventiva does not currently pay a dividend.
Dividend Growth
Inventiva does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IVA.

3.8

News and Social Media Coverage

News Sentiment
Inventiva has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
Search Interest
1 people have searched for IVA on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Inventiva to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inventiva insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.46% of the stock of Inventiva is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inventiva are expected to grow in the coming year, from ($2.21) to ($2.07) per share.
Price to Book Value per Share Ratio
Inventiva has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IVA Stock News Headlines

December 4, 2023 | finance.yahoo.com

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

November 24, 2023 | americanbankingnews.com

Brokerages Set Inventiva S.A. (NASDAQ:IVA) PT at $16.40

December 4, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.

November 22, 2023 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)

November 21, 2023 | finanznachrichten.de

INVENTIVA: Inventiva reports 2023 Third Quarter Financial Information

November 21, 2023 | msn.com

Inventiva reports 9M results

November 21, 2023 | finance.yahoo.com

Inventiva reports 2023 Third Quarter Financial Information¹

November 12, 2023 | lse.co.uk

Inventiva Share Price (IVA.PA)

December 4, 2023 | Financial Alphas (Ad)

Recent Reports Are A Wake-Up Call For Investors

November 9, 2023 | markets.businessinsider.com

Hold Rating on Madrigal Pharmaceuticals Amid Potential and Uncertainties: FDA Review, Commercial Launch, and Mixed Data Impact

November 6, 2023 | finance.yahoo.com

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023

October 27, 2023 | finance.yahoo.com

Non-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51% of market growth- Technavio

October 2, 2023 | markets.businessinsider.com

Positive Prospects for Inventiva: Pivotal NATiV3 Trial Progress, Anticipated LEGEND Study Results, and Expansion into Asian Markets

September 28, 2023 | finanznachrichten.de

INVENTIVA: Inventiva reports its 2023 first-half financial results and provides a corporate update

September 28, 2023 | finance.yahoo.com

Inventiva reports its 2023 first-half financial results and provides a corporate update

September 21, 2023 | markets.businessinsider.com

Investors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Ease

September 21, 2023 | markets.businessinsider.com

Pre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…

September 20, 2023 | marketwatch.com

Inventiva ADRs Rise 9% Following Licensing Deal

September 20, 2023 | finance.yahoo.com

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

September 20, 2023 | finance.yahoo.com

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

September 12, 2023 | msn.com

Industry slow to embrace new fatty liver disease nomenclature

August 31, 2023 | msn.com

urban-gro announces sale of investment for proceeds of $2.3 million

August 31, 2023 | msn.com

Inventiva announced €35.7M funding, eyes future raise to meet obligations

August 31, 2023 | finance.yahoo.com

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

August 14, 2023 | msn.com

Drugmakers still chasing potentially lucrative NASH market, despite setbacks

July 28, 2023 | finanznachrichten.de

INVENTIVA: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

July 28, 2023 | finance.yahoo.com

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

See More Headlines

Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IVA
CUSIP: N/A
CIK: 1756594
Web: www.inventivapharma.com
Phone: 33-3-80-44-75-00
Fax: N/A
Employees: 117
Year Founded: 2011

Price Target and Rating

Average Stock Price Target: $16.40
High Stock Price Target: $35.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +267.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.39
Quick Ratio: 1.37

Sales & Book Value

Annual Sales: $12.83 million
Price / Sales: 17.99
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 3.91

Miscellaneous

Outstanding Shares: 51,750,000
Free Float: 35,192,000
Market Cap: $230.81 million
Optionable: Not Optionable
Beta: 0.92

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Frederic Cren (Age 57)
Co-Founder, CEO & Chairman
Comp: $550.18k
Dr. Pierre Broqua Ph.D. (Age 61)
Co-Founder, Chief Scientific Officer, Deputy CEO & Director
Comp: $412.67k
Mr. Jean Volatier (Age 58)
Chief Financial Officer
Alice Roudot-Ketelers Pharm.D.
Chief Operating Officer
Mr. Eric Duranson L.L.M. (Age 49)
General Counsel
Ms. Nathalie Harroy (Age 56)
Head of Human Resources
Dr. Irena Konstantinova
Head of Biology & Pharmacology
Dr. Michael Cooreman (Age 65)
Chief Medical Officer
Mr. Jean-Paul Dutertre M.D.
Head of Pharmacovigilance

Key Competitors

View All Competitors

Institutional Ownership

Commonwealth Equity Services LLC
Bought 4,155 shares on 10/23/2023
Ownership: 0.047%

View All Institutional Transactions

IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVA shares.
View IVA analyst ratings or view top-rated stocks.
What is Inventiva's stock price target for 2024?: 7 brokers have issued 1-year price targets for Inventiva's stock. Their IVA share price targets range from $11.00 to $35.00. On average, they expect the company's stock price to reach $16.40 in the next year. This suggests a possible upside of 267.7% from the stock's current price.
View analysts price targets for IVA or view top-rated stocks among Wall Street analysts.
How have IVA shares performed in 2023?: Inventiva's stock was trading at $4.46 at the start of the year. Since then, IVA stock has increased by 0.0% and is now trading at $4.46.
View the best growth stocks for 2023 here.
When did Inventiva IPO?: (IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Who are Inventiva's major shareholders?: Inventiva's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.05%).
How do I buy shares of Inventiva?: Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial